<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00116597</url>
  </required_header>
  <id_info>
    <org_study_id>GT1999017/05.050</org_study_id>
    <secondary_id>SNF grant NPF 37 4037-55151</secondary_id>
    <nct_id>NCT00116597</nct_id>
  </id_info>
  <brief_title>Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma</brief_title>
  <official_title>Active Specific Intranodal Immunotherapy With a Recombinant Vaccinia Virus Expressing Three Melanoma Associated Epitopes and Two Costimulatory Molecules, Followed by Immunization With Synthetic Melanoma Associated Epitopes. A Phase I/II Trial in Patients With Stages IIb to IV Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess intranodal immunotherapy in locally advanced to&#xD;
      metastatic melanoma patients (American Joint Committee on Cancer [AJCC] stages IIb to IV).&#xD;
&#xD;
      For this, the investigators capitalize on their previous melanoma clinical trial (published&#xD;
      by Zajac P et al in Human Gene Ther 2003) and take advantage of a proprietary recombinant&#xD;
      vaccinia virus (replication inactivated) expressing 5 minigenes: 3 melanoma associated&#xD;
      antigens and 2 costimulatory molecules. Immunization with the recombinant vaccinia virus is&#xD;
      followed by 3 boosts with soluble, synthetic melanoma associated antigens.&#xD;
&#xD;
      The patients are immunized intranodally (groin lymph node) under ultrasonographic guidance in&#xD;
      an outpatient clinic. The protocol foresees 2 cycles of immunotherapy for alternate weeks and&#xD;
      lasts 15 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators have conducted a phase I/II clinical trial based on the intradermal&#xD;
      administration to stage III/IV melanoma patients of a recombinant vaccinia virus encoding&#xD;
      tumor associated antigens and costimulatory epitopes for the priming of immune responses,&#xD;
      followed by boosts with corresponding synthetic peptides (Zajac P et al in Human Gene Ther&#xD;
      2003). Specific cytotoxic T cells could be induced in a majority of patients following&#xD;
      priming, but sustained responsiveness could not be maintained by peptide boosting on a long&#xD;
      term basis. Emerging evidence supports the notion that expansion of specific T cells requires&#xD;
      trafficking of antigen presenting cells loaded with specific determinants to lymphatic nodes,&#xD;
      as induced, among others, by pro-inflammatory stimuli. Therefore, we now adopt the intranodal&#xD;
      injection of the immunogenic formulations. As for the former melanoma active specific&#xD;
      immunotherapy trial, GM-CSF is used as a supporting cytokine. The epitopes considered are&#xD;
      expressed, either all or some of them, in over 90% of the melanomas in Western countries;&#xD;
      namely, we immunize with Mart-1/Melan-A epitope 27-35, Gp-100 epitope 280-288 and tyrosinase&#xD;
      epitope 1-9. As a consequence, HLA-A2 positivity is mandatory for inclusion in the trial. The&#xD;
      2 costimulatory molecules expressed by cells infected with our replication-incompetent&#xD;
      recombinant vaccinia virus are B7.1 (CD80) and B7.2 (CD86).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety evaluation</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical response</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune response assessment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival (disease-free survival [DFS], overall survival [OS])</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose adaptation</measure>
  </secondary_outcome>
  <enrollment type="Actual">15</enrollment>
  <condition>Melanoma</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Intranodal immunization with a recombinant vaccinia virus expressing 5 transgenes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intranodal booster immunizations with synthetic melanoma associated epitopes</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients older than 18 years&#xD;
&#xD;
          -  Histologically proven melanoma in AJCC stages IIb to IV&#xD;
&#xD;
          -  Resected, recurrent or disseminated disease&#xD;
&#xD;
          -  HLA-A2.1 MHC phenotype&#xD;
&#xD;
          -  Karnofsky performance status equal or higher than 70%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients younger than 18 years&#xD;
&#xD;
          -  Pregnancy or inability to perform anticonception&#xD;
&#xD;
          -  MHC phenotype other than HLA-A2.1&#xD;
&#xD;
          -  Other concurrent malignant disease&#xD;
&#xD;
          -  Estimated life expectancy of less than 6 months&#xD;
&#xD;
          -  Allergic skin diseases, including eczema, psoriasis and neurodermitis&#xD;
&#xD;
          -  Fever or active infection of the respiratory system&#xD;
&#xD;
          -  Concurrent severe cardiac or pulmonary disease (New York Heart Association [NYHA] III&#xD;
             and IV)&#xD;
&#xD;
          -  Significant impairment of liver or kidney function (bilirubin &gt; 30umol/l, GOT &gt;2.5xN,&#xD;
             GPT &gt;2.5xN, alkaline phosphatase &gt;2.5xN, creatinine &gt;1.5xN adapted to the age)&#xD;
&#xD;
          -  Impairment of the immune system (leucocyte counts &lt;3000/mm3 or granulocytes counts&#xD;
             &lt;1500/mm3)&#xD;
&#xD;
          -  Concurrent immunosuppressive therapy&#xD;
&#xD;
          -  Preexisting severe anemia (hemoglobin lower than 80 g/l)&#xD;
&#xD;
          -  Preexisting thrombocytopenia (platelet counts lower than 75,000/ul)&#xD;
&#xD;
          -  Ongoing chemotherapy or chemotherapy completed less than 6 weeks before enrollment in&#xD;
             the trial&#xD;
&#xD;
          -  Any medical or psychiatric condition which, in the opinion of the treating physician&#xD;
             or principal investigator, would unacceptably reduce the safety of the proposed&#xD;
             treatment, would impair the delivery of treatment, or would preclude obtaining&#xD;
             voluntary informed consent&#xD;
&#xD;
          -  Patients receiving any other concurrent investigational treatment, or any other&#xD;
             concurrent treatment for their cancer&#xD;
&#xD;
          -  Patients who cannot avoid close contact with children less than 3 years of age or with&#xD;
             immunocompromised household members&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Adamina, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Oertli, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Heberer, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giulio C Spagnoli, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Walter R Marti, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.icfs-basel.ch/english/onco.htm</url>
    <description>Website of the sponsor institute ICFS of the University of Basel, Switzerland</description>
  </link>
  <reference>
    <citation>Spagnoli GC, Zajac P, Marti WR, Oertli D, Padovan E, Noppen C, Kocher T, Adamina M, Heberer M. Cytotoxic T-cell induction in metastatic melanoma patients undergoing recombinant vaccinia virus-based immuno-gene therapy. Recent Results Cancer Res. 2002;160:195-201.</citation>
    <PMID>12079214</PMID>
  </reference>
  <reference>
    <citation>Zajac P, Schütz A, Oertli D, Noppen C, Schaefer C, Heberer M, Spagnoli GC, Marti WR. Enhanced generation of cytotoxic T lymphocytes using recombinant vaccinia virus expressing human tumor-associated antigens and B7 costimulatory molecules. Cancer Res. 1998 Oct 15;58(20):4567-71.</citation>
    <PMID>9788602</PMID>
  </reference>
  <reference>
    <citation>Adamina M, Oertli D. Antigen specific active immunotherapy: lessons from the first decade. Swiss Med Wkly. 2005 Apr 16;135(15-16):212-21.</citation>
    <PMID>15971113</PMID>
  </reference>
  <results_reference>
    <citation>Zajac P, Oertli D, Marti W, Adamina M, Bolli M, Guller U, Noppen C, Padovan E, Schultz-Thater E, Heberer M, Spagnoli G. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum Gene Ther. 2003 Nov 1;14(16):1497-510.</citation>
    <PMID>14577912</PMID>
  </results_reference>
  <results_reference>
    <citation>Oertli D, Marti WR, Zajac P, Noppen C, Kocher T, Padovan E, Adamina M, Schumacher R, Harder F, Heberer M, Spagnoli GC. Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo. Hum Gene Ther. 2002 Mar 1;13(4):569-75.</citation>
    <PMID>11874634</PMID>
  </results_reference>
  <results_reference>
    <citation>Adamina M, Rosenthal R, Weber WP, Frey DM, Viehl CT, Bolli M, Huegli RW, Jacob AL, Heberer M, Oertli D, Marti W, Spagnoli GC, Zajac P. Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma. Mol Ther. 2010 Mar;18(3):651-9. doi: 10.1038/mt.2009.275. Epub 2009 Nov 24.</citation>
    <PMID>19935776</PMID>
  </results_reference>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>June 29, 2005</study_first_submitted>
  <study_first_submitted_qc>June 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2005</study_first_posted>
  <last_update_submitted>December 1, 2009</last_update_submitted>
  <last_update_submitted_qc>December 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Michel Adamina, M.D., P.D., M.Sc.</name_title>
    <organization>University Hospital Basel</organization>
  </responsible_party>
  <keyword>Active Specific Immunotherapy</keyword>
  <keyword>Intranodal</keyword>
  <keyword>Cancer</keyword>
  <keyword>Melanoma stages IIb to IV</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>Recombinant Vaccinia virus</keyword>
  <keyword>HLA-A2</keyword>
  <keyword>Mart-1/Melan-A, Gp-100, tyrosinase</keyword>
  <keyword>Clinical Trial</keyword>
  <keyword>Phase I/II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccinia</mesh_term>
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

